102573-84-2

Basic information

• Product Name: 1,3-Dioxane-5-carboxaldehyde, 2,2-dimethyl- (9CI)
• Synonyms: 1,3-Dioxane-5-carboxaldehyde, 2,2-dimethyl- (9CI);1,3-Dioxane-5-carboxaldehyde, 2,2-diMethyl-;2,2-DiMethyl-[1,3]dioxane-5-carbaldehyde
• CAS NO: 102573-84-2
• Molecular Formula: C₇H₁₂O₃
• Molecular Weight: 144.16838
• Product Categories: ALDEHYDE
• Mol File: 102573-84-2.mol

Chemical Properties

• Boiling Point: 194.6±25.0 °C(Predicted)
• Appearance: /
• Density: 1.079±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 1,3-Dioxane-5-carboxaldehyde, 2,2-dimethyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Dioxane-5-carboxaldehyde, 2,2-dimethyl- (9CI)(102573-84-2)
• EPA Substance Registry System: 1,3-Dioxane-5-carboxaldehyde, 2,2-dimethyl- (9CI)(102573-84-2)

Safety Data

• Hazardous Substances Data: 102573-84-2(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
1,3-Dioxane-5-carboxaldehyde, 2,2-dimethyl(9CI) is used as an intermediate in the synthesis of pheromones and other chemical derivatives. Its unique chemical structure allows for the creation of a variety of compounds with specific properties and applications.
Used in Research and Development:
In the research and development sector, 1,3-Dioxane-5-carboxaldehyde, 2,2-dimethyl(9CI) is used as a building block for the production of various materials. Its versatility in chemical reactions makes it a valuable component in the development of new products and processes.
Used in Adhesives Industry:
1,3-Dioxane-5-carboxaldehyde, 2,2-dimethyl(9CI) is used as a component in the formulation of adhesives. Its chemical properties contribute to the adhesive's performance, such as bonding strength and durability.
Used in Polymer Production:
1,3-Dioxane-5-carboxaldehyde, 2,2-dimethyl(9CI) is utilized in the production of polymers, where it serves as a monomer or a reactant in polymerization reactions. The resulting polymers find applications in various industries, including plastics, coatings, and textiles.
Used in Pharmaceutical Industry:
1,3-Dioxane-5-carboxaldehyde, 2,2-dimethyl(9CI) is used in the pharmaceutical industry as a building block for the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with specific therapeutic properties.

Upstream product

• 4728-12-5 2,2-dimethyl-5-hydroxymethyl-1,3-dioxane 

Downstream Products

• 355423-31-3 2-[(E)-2-(2,2-Dimethyl-[1,3]dioxan-5-yl)-vinyl]-1,3-dimethyl-4-oxo-cyclohex-2-enecarboxylic acid methyl ester 
• 364330-80-3 3-[(E)-2-(2,2-Dimethyl-[1,3]dioxan-5-yl)-vinyl]-4-hydroxymethyl-2,4-dimethyl-cyclohex-2-enone 
• 364330-79-0 {4-(tert-butyl-dimethyl-silanyloxy)-2-[2-(2,2-dimethyl-[1,3]dioxan-5-yl)-vinyl]-1,3-dimethyl-cyclohexa-2,4-dienyl}-methanol 
• 364330-78-9 4-(tert-butyl-dimethyl-silanyloxy)-2-[2-(2,2-dimethyl-[1,3]dioxan-5-yl)-vinyl]-1,3-dimethyl-cyclohexa-2,4-dienecarboxylic acid methyl ester 
• 1395878-12-2 C₃₈H₄₂F₃NO₉ 
• 1395878-11-1 C₃₈H₄₂F₃NO₉ 
• 1395877-94-7 C₂₈H₃₅NO₇ 
• 1039747-49-3 C₂₈H₃₇N₃O₂ 
• 1029623-88-8 C₂₇H₃₆N₄O₂ 
• 1231170-13-0 1-(2,2-dimethyl-[1,3]dioxan-5-ylmethyl)-4-(4-trifluoromethoxyphenyl)piperazine 
• 155818-06-7 {(1S,2S)-2-[(E)-2-(2,2-Dimethyl-[1,3]dioxan-5-yl)-vinyl]-1,3-dimethyl-4-triisopropylsilanyloxy-cyclohex-3-enyl}-methanol 
• 155818-05-6 (1S,2R)-2-[(E)-2-(2,2-Dimethyl-[1,3]dioxan-5-yl)-vinyl]-1,3-dimethyl-4-triisopropylsilanyloxy-cyclohex-3-enecarbaldehyde 
• 155818-07-8 (S)-3-[(E)-2-(2,2-Dimethyl-[1,3]dioxan-5-yl)-vinyl]-4-hydroxymethyl-2,4-dimethyl-cyclohex-2-enone 
• 141081-72-3 (Rs)-2,2-dimethyl-5-<3-oxo-4-(p-tolylsulfinyl)butyl>-1,3-dioxane 

Relevant articles and documents

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES

The invention relates to anti-CD98 antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES

The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

BCL XL INHIBITORY COMPOUNDS HAVING LOW CELL PERMEABILITY AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME

The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.

ANTIBACTERIAL AGENTS

Antibacterial compounds of formula (I) are provided, as well as stereoisomers and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.

Enantioselective total synthesis of (+)-cassiol

(Chemical Equation Presented) An enantioselective total synthesis of (+)-cassiol is reported. The complex derived from Pd2(pmdba) 3 and enantiopure t-BuPHOX ligand catalyzes enantioconvergent decarboxylative alkylation to generate the quaternary carbon stereocenter at an early stage. The overall synthetic strategy involves a convergent late-stage coupling of two fragments. The synthesis features a longest linear sequence of eight steps.

SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS

Disclosed are new substituted pyrazole and triazole compounds of Formula (I) and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses thereof

CYCLIZED DERIVATIVES AS EG-5 INHIBITORS

The present invention relates to new substituted imidazole compounds have the following Formula (I) and to the pharmaceutically acceptable salts, esters, or prodrugs thereof, to compositions of the compounds together with pharmaceutically acceptable carriers, and to uses of the compounds: (I).

Facile synthesis of (±)-paeonilide

(Chemical Equation Presented) (±)-Paeonilide, a novel monoterpenoid metabolite from the roots of Paeonia delavayi showing anti-platelet activating factor activity, is convergently synthesized in five steps with 59% overall yield. The application of benzoyl peroxide-promoted radical addition of unsaturated ester to aldehyde and subsequent topologically favored cyclization greatly simplified the synthesis.

NITROIMIDAZOLE COMPOUNDS

The present invention relates to certain nitroimidazole compounds, which have interesting pharmaceutical properties. In particular, the compounds are useful in the treatment and/or prevention of infections such as those caused by Mycobacterium tuberculosis, Trypanosoma cruzi or Leishmania donovani. The invention also relates to pharmaceutical compositions containing the compounds, as well as processes for their preparation.